Thiazolidinedione Drugs Promote Onset, Alter Characteristics, and Increase Mortality of Ischemic Ventricular Fibrillation in Pigs

Cardiac ion channel modulation by the hypoglycaemic agent rosiglitazone

(2011) JC Hancox   BRITISH JOURNAL OF PHARMACOLOGY

Mechanisms of Defibrillation

(2010) Derek J. Dosdall et al.   Annual Review of Biomedical Engineering

Risk of Cardiovascular Events and All-Cause Mortality in Patients Treated With Thiazolidinediones in a Managed-Care Population

(2010) Debra A. Wertz et al.  

Changes in Glitazone Use Among Office-Based Physicians in the U.S., 2003-2009

(2010) A. Cohen et al.   DIABETES CARE

Serine-385 phosphorylation of inwardly rectifying K+ channel subunit (Kir6.2) by AMP-dependent protein kinase plays a key role in rosiglitazone-induced closure of the KATP channel and insulin secretion in rats

(2009) T.-J. Chang et al.   DIABETOLOGIA

Oral Glyburide, But Not Glimepiride, Blocks the Infarct-Size Limiting Effects of Pioglitazone

(2008) Yumei Ye et al.   CARDIOVASCULAR DRUGS AND THERAPY

Reassessing the Cardiovascular Risks and Benefits of Thiazolidinediones

(2008) Andrew Zinn et al.   CLINICAL CARDIOLOGY

Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs

(2008) L. Lu et al.   DIABETOLOGIA